Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial
dc.contributor.author | Fontana, Robert John | en_US |
dc.contributor.author | Israel, Jonathan | en_US |
dc.contributor.author | LeClair, Paula | en_US |
dc.contributor.author | Banner, Barbara F. | en_US |
dc.contributor.author | Tortorelli, Kristina | en_US |
dc.contributor.author | Grace, Norman | en_US |
dc.contributor.author | Levine, Robert A. | en_US |
dc.contributor.author | Fiarman, Gale | en_US |
dc.contributor.author | Thiim, Michael | en_US |
dc.contributor.author | Tavill, Anthony S. | en_US |
dc.contributor.author | Bonkovsky, Herbert L. | en_US |
dc.date.accessioned | 2006-04-19T13:49:56Z | |
dc.date.available | 2006-04-19T13:49:56Z | |
dc.date.issued | 2000-03 | en_US |
dc.identifier.citation | Fontana, Robert J.; Israel, Jonathan; LeClair, Paula; Banner, Barbara F.; Tortorelli, Kristina; Grace, Norman; Levine, Robert A.; Fiarman, Gale; Thiim, Michael; Tavill, Anthony S.; Bonkovsky, Herbert L. (2000)."Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial." Hepatology 31(3): 730-736. <http://hdl.handle.net/2027.42/34777> | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34777 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10706565&dopt=citation | en_US |
dc.description.abstract | Patients with chronic hepatitis C and low serum and hepatic iron stores may have an improved response to interferon (IFN). We tested whether iron reduction before and during IFN therapy would lead to an improved sustained biochemical and virological response compared with IFN alone. Eighty-two previously untreated patients with chronic hepatitis C were randomized to either: group A IFN-Α2b 3 MU 3 times per week for 6 months, or group B iron reduction before and during IFN-Α2b 3 MU 3 times per week for 6 months. Group B patients had lower mean serum alanine transaminase (ALT) levels than group A patients during treatment and follow-up. Group B patients had significantly lower mean hepatitis C virus (HCV)-RNA levels at treatment weeks 4 and 12 ( P < .05). Serum HCV RNA was undetectable at the end of treatment in 15 group B patients compared with 7 group A patients ( P = .03); 7 group B patients and 3 group A patients had persistently undetectable serum HCV RNA 24 weeks after the end of therapy ( P = .20). Paired pre- and posttreatment liver biopsies in 18 group B patients demonstrated significant improvements in 2 of the 3 inflammation scores of the Knodell histological activity index ( P < .05). No changes occurred in the paired biopsies from 15 group A patients. We conclude that iron reduction via therapeutic phlebotomy improves the end-of-treatment virological and histological response to short-term IFN therapy. Additional studies are needed to determine if iron reduction in combination with higher doses or longer duration of IFN may be of benefit. | en_US |
dc.format.extent | 128680 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | W.B. Saunders | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Hepatology | en_US |
dc.title | Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical School, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | State University of New York Health Sciences Center at Syracuse, NY ; Division of Gastroenterology, University of Michigan Medical School, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109. fax: (734) 936-7392 | en_US |
dc.contributor.affiliationother | Hartford Hospital and University of Connecticut School of Medicine, Hartford, CT | en_US |
dc.contributor.affiliationother | University of Massachusetts Medical School and U. Mass Memorial Health Care, Worcester, MA | en_US |
dc.contributor.affiliationother | University of Massachusetts Medical School and U. Mass Memorial Health Care, Worcester, MA | en_US |
dc.contributor.affiliationother | University of Massachusetts Medical School and U. Mass Memorial Health Care, Worcester, MA | en_US |
dc.contributor.affiliationother | Faulkner Hospital and Tufts University School of Medicine, Boston, MA | en_US |
dc.contributor.affiliationother | Lahey Clinic, Burlington, MA | en_US |
dc.contributor.affiliationother | Lahey Clinic, Burlington, MA | en_US |
dc.contributor.affiliationother | Mt. Sinai Medical Center and Case Western Reserve University, Cleveland, OH | en_US |
dc.contributor.affiliationother | University of Massachusetts Medical School and U. Mass Memorial Health Care, Worcester, MA | en_US |
dc.identifier.pmid | 10706565 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34777/1/510310325_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/hep.510310325 | en_US |
dc.identifier.source | Hepatology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.